ACS 化学神经科学分子特写：二甲胺四环素。
ACS chemical neuroscience molecule spotlight on dimebon.
机构信息
Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
出版信息
ACS Chem Neurosci. 2010 Sep 15;1(9):587-8. doi: 10.1021/cn1000588.
Abstract
Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.
摘要
地美波恩（拉替普啶）是一种抗组胺药物，自 20 世纪 80 年代初在俄罗斯临床应用以来，辉瑞公司和 Medivation 公司一直在联合研究用于治疗阿尔茨海默病患者。一项关键性 3 期临床试验（CONNECTION）的结果显示，地美波恩（拉替普啶）未能达到其主要或次要疗效终点。
相似文献
1
ACS chemical neuroscience molecule spotlight on dimebon.
ACS Chem Neurosci. 2010 Sep 15;1(9):587-8. doi: 10.1021/cn1000588.
2
Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
Curr Opin Investig Drugs. 2010 Jan;11(1):80-91.
3
The rise and fall of Dimebon.
Drug News Perspect. 2010 Oct;23(8):518-23. doi: 10.1358/dnp.2010.23.8.1500435.
4
Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model.
Autophagy. 2013 Apr;9(4):617-8. doi: 10.4161/auto.23487. Epub 2013 Feb 4.
5
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.
Transl Psychiatry. 2013 Dec 3;3(12):e332. doi: 10.1038/tp.2013.97.
6
Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis.
J Alzheimers Dis. 2014;38(1):155-64. doi: 10.3233/JAD-130872.
7
ACS chemical neuroscience molecule spotlight on BMS-708163.
ACS Chem Neurosci. 2012 Mar 21;3(3):149-50. doi: 10.1021/cn3000179.
8
Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.
Ann N Y Acad Sci. 2001 Jun;939:425-35. doi: 10.1111/j.1749-6632.2001.tb03654.x.
9
ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic.
ACS Chem Neurosci. 2011 Jun 15;2(6):279-80. doi: 10.1021/cn2000469.
10
Dimebon in Alzheimer's disease: old drug for new indication.
Lancet. 2008 Jul 19;372(9634):179-80. doi: 10.1016/S0140-6736(08)61046-6.
引用本文的文献
1
Efficient synthesis of 3H-indoles enabled by the lead-mediated α-arylation of β-ketoesters or γ-lactams using aryl azides.
Org Lett. 2014 Jun 6;16(11):2916-9. doi: 10.1021/ol5010615. Epub 2014 May 27.
2
The contribution of lysosomotropism to autophagy perturbation.
PLoS One. 2013 Nov 22;8(11):e82481. doi: 10.1371/journal.pone.0082481. eCollection 2013.
3
Ruthenium-catalyzed γ-carbolinium ion formation from aryl azides; synthesis of dimebolin.
Org Lett. 2011 May 20;13(10):2726-9. doi: 10.1021/ol2008268. Epub 2011 Apr 25.
本文引用的文献
1
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Lancet. 2008 Jul 19;372(9634):207-15. doi: 10.1016/S0140-6736(08)61074-0.
2
Dimebon improves learning in animals with experimental Alzheimer's disease.
Bull Exp Biol Med. 2000 Jun;129(6):544-6. doi: 10.1007/BF02434871.
Zotero 插件